Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Glecirasib - Jacobio Pharmaceuticals

Drug Profile

Glecirasib - Jacobio Pharmaceuticals

Alternative Names: JAB-21000; JAB-21822

Latest Information Update: 06 Jun 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Jacobio Pharmaceuticals
  • Class Antineoplastics; Small molecules
  • Mechanism of Action KRAS protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pancreatic cancer
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preregistration Non-small cell lung cancer
  • Phase II Pancreatic cancer
  • Phase I/II Colorectal cancer; Intestinal cancer; Solid tumours

Most Recent Events

  • 01 Jun 2024 Phase-III clinical trials in Non-small cell lung cancer (Combination therapy, First-line therapy, Late-stage disease, Metastatic disease, Inoperable/Unresectable) in China (PO) (NCT06416410)
  • 01 Jun 2024 Glecirasib receives priority review status for Non-small cell lung cancer with KRAS G12C mutation in China
  • 01 Jun 2024 National Medical Products Administration of China accepts NDA for Glecirasib for Non-small cell lung cancer for review
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top